Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype

◆ TRIAL DATA

A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not respond well to immunotherapy. (Clinical Colorectal Cancer)